728 A phase 1/2 study of JK08, an IL-15 antibody fusion protein targeting CTLA-4, in patients with advanced solid tumors
Nuria Kotecki(Centre Oscar Lambret), Naimish Pandya(Integrated BioTherapeutics (United States)), Vladimir Galvao(Hebron University), Sylvie Rottey(Ghent University Hospital), Valentina Boni, Shalabh Singhal(Integrated BioTherapeutics (United States)), Brant Delafontaine(Ghent University Hospital), Omar Saavedra(Hospital Quirónsalud Barcelona), Amanda McEwen, Elena Garralda(Memorial Sloan Kettering Cancer Center), Samuel L. Murphy(Integrated BioTherapeutics (United States))
Cited by 1
Related Papers
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|835
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study
|The Lancet Oncology|2019|564
Precision Targeted Therapy with BLU-667 for <i>RET</i>-Driven Cancers
|Cancer Discovery|2018|397
Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1–Low/Negative Recurrent or Metastatic HNSCC
|JAMA Oncology|2018|315
Single-Agent Divarasib (GDC-6036) in Solid Tumors with a <i>KRAS</i> G12C Mutation
|New England Journal of Medicine|2023|307